47 Respiratory CRO and CDMO vendors

What kind of CRO work does a Respiratory program need?

Respiratory covers a wide spread of disease, and the CRO work changes sharply across it. Obstructive disease (asthma, COPD), interstitial and fibrotic lung disease (idiopathic pulmonary fibrosis), cystic fibrosis, pulmonary arterial hypertension, and acute conditions like ARDS each pull on different models, endpoints, and delivery expertise. A supplier that runs a clean ovalbumin or house-dust-mite asthma model is not automatically the right shop for a bleomycin-induced fibrosis study or a chronic cigarette-smoke COPD model. Match the work to the indication first, before anything else.

On the discovery and preclinical side, the bench work leans heavily on airway biology and lung-specific delivery. Buyers source in vitro work in human bronchial epithelial cells at air-liquid interface, mucociliary clearance and mucus-rheology assays, and inflammation readouts (cytokine panels, eosinophil and neutrophil counts in bronchoalveolar lavage). In vivo, the common models are antigen-challenge asthma, smoke-exposure or elastase COPD, bleomycin fibrosis, and LPS-induced acute lung injury, read out by lung function (airway resistance and compliance via forced-oscillation), histopathology, and BAL cellularity. Inhalation toxicology and aerosol characterization (particle size by cascade impactor, deposition modeling) is its own specialty, and a real differentiator for inhaled programs.

Delivery is where Respiratory diverges most from a systemic small molecule. If the drug goes to the lung, the formulation and device matter as much as the molecule: dry powder inhalers, pressurized metered-dose inhalers, nebulized solutions, and soft-mist devices each carry different CDMO work, from particle engineering and spray drying to device fill-finish and aerodynamic particle-size distribution testing. Sponsors developing an inhaled product source CDMO partners for formulation, aerosol performance, and stability under the conditions a device sees in real use.

On the clinical side, Respiratory trials run under GCP and turn on well-established efficacy endpoints. Spirometry (FEV1, FVC, and the FEV1/FVC ratio) is the backbone of obstructive-disease trials; six-minute walk distance and FVC decline anchor fibrosis and PAH studies; exacerbation rate, rescue-medication use, and patient-reported outcomes (ACQ, SGRQ) round out the picture. Buyers source clinical operations, sites with pulmonary function labs and centralized spirometry overread, data management, biostatistics, pharmacovigilance, and clinical supply, often including device handling and patient training on inhaler technique.

How do you choose a CRO for Respiratory?

The headline rate tells you almost nothing about whether a Respiratory program will run clean. What predicts that is specific, checkable experience in your indication and your route of delivery. Run two or three candidates against the same written scope and weigh these:

• Therapeutic-area and indication experience: confirm the team has actually run your disease, not just Respiratory in general. Ask for the specific models (house-dust-mite asthma, smoke or elastase COPD, bleomycin fibrosis) with historical control data already in hand, so you are not paying to stand a model up for the first time.
• Delivery and device expertise: if the drug is inhaled or intranasal, confirm the supplier handles aerosol generation, dosing to the lung, and aerodynamic particle-size testing. Systemic-dosing competence does not transfer to an inhaled program.
• Relevant disease models or patient access: preclinically, that means validated, characterized lung models. Clinically, it means sites with working pulmonary function labs, access to your patient population (severe asthma, IPF, and CF enroll slowly), and centralized spirometry to keep FEV1 readings comparable across sites.
• Regulatory track record: check the supplier has supported filings with the agencies you plan to use (FDA, EMA), and for inhaled products understands the device and combination-product expectations that come with them. GLP status for pivotal inhalation toxicology is non-negotiable.
• Data quality: clean, well-documented lung-function and histopathology data, validated or fit-for-purpose bioanalytical methods that travel, centralized overread of spirometry, and honest reporting of the cohorts or models that did not work, not only the ones that did.
• Capacity and turnaround: a strong inhalation lab booked solid for months may be slower than a good one with an open slot. Confirm real capacity, report turnaround (not just bench time), and how change orders are priced when a study slips or a cohort fails.